https://www.selleckchem.com/products/gdc-0068.html
Monitoring HER2ECD levels during trastuzumab monotherapy could help defining the optimal time to introduce chemotherapy. TRIAL REGISTRATION Registration Number by ClinicalTrials.gov NCT00004935, Trial number SAKK22/99. Registered on 27 January 2003.BACKGROUND The rate of S68G mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase has increased and is closely related to the K65R mutation among CRF01_AE-infected patients who failed treatment. We aimed to explore the temporal association of S68G and K65R mutations a
Like
Comment
Share
